Toxicogenomic predictive modeling: Emerging opportunities for more efficient drug discovery and development

Drug discovery companies are coming under increasing pressure to prove the long-term safety of their products more precisely, and to provide more data on them. As highlighted by Vioxx, for many drugs, the existence of adverse drug reactions (ADRs) becomes apparent once the compound has been extensively prescribed and a population base of considerable size has been exposed to the therapeutic agent. The ability to make decisions regarding...